我国生物医药创新投入及其政策成因分析——基于中美欧创新投入现状的实证评价

Analysis of Biopharmaceutical Innovation Investment in China and Its Policy Causes——On the Basis of the Status Quo of Innovation Investment in United States,Europe and China by Empirical evaluation

近年来,我国创新药物研发愈发受到政府和企业的重视,创新投入逐年增加,但与发达国家相比仍存巨大差距。采用量化比较的手法,对中美欧创新药物研发投入及资金结构进行实证评价,旨在深入分析我国生物医药投入现状及其政策成因,为完善我国生物医药创新制度提供建议。

During these years,the RD of China＇s innovative drug has attracted more and more attention.Although the RD investments are increasing year by year,obvious gap is still existing when compared with foreign.This paper used quantitative comparison to compare the input and the construction of RD investments of the US,EU and China innovative drugs by empirical evaluation,aiming to profoundly research the present situation and policy causes of the RD investments of Chinese biopharmaceutical industry.Furthermore,we would like to make some suggestions to promote the innovative institution of Chinese biopharmaceutical industry.